Aptevo Therapeutics sees 100% remission rate in leukemia trial, shares surge 16%.

Aptevo Therapeutics shares surged 16% after the company reported promising clinical data from its RAINIER trial evaluating mipletamig, a therapy for acute myeloid leukemia. Cohort 3 of the trial achieved a 100% remission rate, with 40% of patients reaching MRD-negative status. The therapy demonstrated a favorable safety profile in combination with venetoclax and azacitidine. The results reinforce Aptevo's conviction that mipletamig is a differentiated medicine with the potential to elevate outcomes for patients with limited options.